L. Puig

29.5k total citations · 7 hit papers
626 papers, 18.2k citations indexed

About

L. Puig is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, L. Puig has authored 626 papers receiving a total of 18.2k indexed citations (citations by other indexed papers that have themselves been cited), including 373 papers in Immunology, 250 papers in Dermatology and 105 papers in Rheumatology. Recurrent topics in L. Puig's work include Psoriasis: Treatment and Pathogenesis (324 papers), Dermatology and Skin Diseases (183 papers) and Health Systems, Economic Evaluations, Quality of Life (88 papers). L. Puig is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (324 papers), Dermatology and Skin Diseases (183 papers) and Health Systems, Economic Evaluations, Quality of Life (88 papers). L. Puig collaborates with scholars based in Spain, United States and Germany. L. Puig's co-authors include Giampiero Girolomoni, María Teresa Fernández‐Figueras, Mark Lebwohl, Kristian Reich, Richard G. Langley, Juliet N. Barker, Arthur Kavanaugh, Tiago Torres, Kim Papp and C. Paul and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

L. Puig

601 papers receiving 17.8k citations

Hit Papers

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 ... 2010 2026 2015 2020 2014 2013 2018 2010 2014 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
    2014 1.5k citations Mark Lebwohl, Kristian Reich et al. profile →
  2. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    2013 606 citations Alice B. Gottlieb, L. Puig et al. profile →
  3. Epidemiology of atopic dermatitis in adults: Results from an international survey
    2018 574 citations L. Puig et al. profile →
  4. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
    2010 538 citations L. Puig et al. profile →
  5. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
    2014 508 citations L. Puig, Alice B. Gottlieb et al. profile →
  6. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    2018 452 citations Bruce Strober, Mark Lebwohl et al. profile →
  7. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
    2014 411 citations Mark Lebwohl, L. Puig et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Puig Spain 57 11.2k 7.7k 3.8k 2.5k 2.2k 626 18.2k
C. Paul France 68 8.8k 0.8× 8.8k 1.1× 3.0k 0.8× 1.9k 0.8× 1.1k 0.5× 420 16.5k
Alan Menter United States 80 19.1k 1.7× 12.2k 1.6× 4.7k 1.2× 1.9k 0.8× 2.6k 1.2× 387 25.4k
Giampiero Girolomoni Italy 81 12.5k 1.1× 9.9k 1.3× 3.7k 1.0× 2.4k 1.0× 1.1k 0.5× 558 23.7k
Kristian Reich Germany 80 20.2k 1.8× 14.0k 1.8× 5.0k 1.3× 2.2k 0.9× 2.8k 1.2× 497 26.2k
Alice B. Gottlieb United States 90 23.1k 2.1× 12.3k 1.6× 8.9k 2.4× 2.3k 0.9× 5.4k 2.4× 602 31.4k
Wolf‐­Henning Boehncke Germany 55 8.7k 0.8× 4.4k 0.6× 2.7k 0.7× 859 0.3× 1.5k 0.7× 356 13.2k
Mark Lebwohl United States 94 23.0k 2.1× 18.1k 2.4× 5.7k 1.5× 4.1k 1.6× 2.8k 1.2× 847 36.1k
Lone Skov Denmark 58 6.6k 0.6× 5.5k 0.7× 1.9k 0.5× 924 0.4× 660 0.3× 389 12.9k
Juliet N. Barker United States 85 17.3k 1.5× 9.0k 1.2× 2.8k 0.7× 2.9k 1.2× 8.4k 3.8× 559 31.3k
Enno Christophers Germany 66 10.1k 0.9× 6.0k 0.8× 2.0k 0.5× 1.9k 0.8× 1.0k 0.5× 362 18.9k

Countries citing papers authored by L. Puig

Since Specialization
Citations

This map shows the geographic impact of L. Puig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Puig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Puig more than expected).

Fields of papers citing papers by L. Puig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Puig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Puig. The network helps show where L. Puig may publish in the future.

Co-authorship network of co-authors of L. Puig

This figure shows the co-authorship network connecting the top 25 collaborators of L. Puig. A scholar is included among the top collaborators of L. Puig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Puig. L. Puig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cantó, Elisabet, Marta Prado, Eva Vilarrasa, et al.. (2025). Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. International Journal of Molecular Sciences. 26(17). 8118–8118.
2.
3.
Puig, L., et al.. (2024). Ustekinumab Biosimilars. SHILAP Revista de lepidopterología. 4(4). 407–424. 2 indexed citations
4.
Augustin, Matthias, Alice B. Gottlieb, Mark Lebwohl, et al.. (2024). Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatology and Therapy. 14(10). 2841–2857. 6 indexed citations
5.
Puig, L., et al.. (2024). New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics. 16(2). 239–239. 20 indexed citations
6.
Paller, Amy S., Jonathan I. Silverberg, Michael J. Cork, et al.. (2023). The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 7(2). s139–s139. 1 indexed citations
7.
Puig, L., Siew Eng Choon, Alice B. Gottlieb, et al.. (2023). Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology. 37(4). 737–752. 39 indexed citations
8.
9.
Kokolakis, Georgios, Richard B. Warren, Bruce Strober, et al.. (2022). Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal of Dermatology. 188(3). 330–340. 18 indexed citations
10.
Reich, Kristian, Curdin Conrad, Lars Erik Kristensen, et al.. (2021). Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. Journal of Dermatological Treatment. 33(3). 1652–1660. 24 indexed citations
11.
Puig, L., J.M. Carrascosa, & J. Notario. (2020). Biosimilares en el tratamiento de la psoriasis. Actualización. Actas Dermo-Sifiliográficas. 111(10). 809–814. 6 indexed citations
12.
Cubiró, Xavier, et al.. (2020). Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. International Journal of Dermatology. 60(3). e112–e114. 8 indexed citations
13.
14.
Obón‐Santacana, Mireia, Mireia Vilardell, Anna Carreras, et al.. (2018). GCAT|Genomes for life: a prospective cohort study of the genomes of Catalonia. BMJ Open. 8(3). e018324–e018324. 31 indexed citations
15.
Cohen, Arnon D., Jashin J. Wu, L. Puig, et al.. (2017). Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology. 177(6). 1495–1502. 33 indexed citations
16.
Vilarrasa, Eva, et al.. (2016). ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. Journal of the American Academy of Dermatology. 74(6). 1066–1072. 53 indexed citations
17.
Yélamos, Oriol & L. Puig. (2015). Systemic methotrexate for the treatment of psoriasis. Expert Review of Clinical Immunology. 11(5). 553–563. 49 indexed citations
18.
Jp, Ortonne, et al.. (2009). Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology and Venereology. 23(12). 1435–1444. 80 indexed citations
19.
García-Navarro, Xavier, et al.. (2007). Lupus eritematoso sistémico. 21(7). 44–48.
20.
Dalmau, Josep, L. Puig, Montserrat Gilaberte, et al.. (2006). Manifestaciones cutáneas en pacientes trasplantados: estudio de 63 pacientes. Revista Medicina Cutánea Ibero-Latino-Americana. 34(5). 216–222.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Paul Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Alice B. Gottlieb Breakdown of academic impact, for papers by Wolf‐­Henning Boehncke Breakdown of academic impact, for papers by Mark Lebwohl Breakdown of academic impact, for papers by Lone Skov Breakdown of academic impact, for papers by Juliet N. Barker Breakdown of academic impact, for papers by Enno Christophers
Rankless by CCL
2026